110 related articles for article (PubMed ID: 20831882)
1. The in vitro evaluation of solithromycin (CEM-101) against pathogens isolated in the United States and Europe (2009).
Farrell DJ; Castanheira M; Sader HS; Jones RN
J Infect; 2010 Dec; 61(6):476-83. PubMed ID: 20831882
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates.
Farrell DJ; Sader HS; Castanheira M; Biedenbach DJ; Rhomberg PR; Jones RN
Int J Antimicrob Agents; 2010 Jun; 35(6):537-43. PubMed ID: 20211548
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial characterisation of solithromycin (CEM-101), a novel fluoroketolide: activity against staphylococci and enterococci.
Putnam SD; Sader HS; Farrell DJ; Biedenbach DJ; Castanheira M
Int J Antimicrob Agents; 2011 Jan; 37(1):39-45. PubMed ID: 21075602
[TBL] [Abstract][Full Text] [Related]
4. CEM-101, a novel fluoroketolide: antimicrobial activity against a diverse collection of Gram-positive and Gram-negative bacteria.
Putnam SD; Castanheira M; Moet GJ; Farrell DJ; Jones RN
Diagn Microbiol Infect Dis; 2010 Apr; 66(4):393-401. PubMed ID: 20022192
[TBL] [Abstract][Full Text] [Related]
5. Surveillance of the activity of solithromycin (CEM-101) against bacteria from respiratory tract infections.
Hawser S; Morrissey I; Lemos B; Keedy K; Fernandes P
Int J Antimicrob Agents; 2017 Jul; 50(1):17-22. PubMed ID: 28483717
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of solithromycin and its metabolites, CEM-214 and N-acetyl-CEM-101, against 100 clinical Ureaplasma spp. isolates compared with azithromycin.
Furfaro LL; Spiller OB; Keelan JA; Payne MS
Int J Antimicrob Agents; 2015 Sep; 46(3):319-24. PubMed ID: 26141231
[TBL] [Abstract][Full Text] [Related]
7. Multicenter evaluation of the in vitro activity of dalbavancin tested against staphylococci and streptococci in 5 European countries: results from the DECIDE Surveillance Program (2007).
Biedenbach DJ; Jones RN
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):177-84. PubMed ID: 19249179
[TBL] [Abstract][Full Text] [Related]
8. In-vitro activity of solithromycin against anaerobic bacteria from the normal intestinal microbiota.
Weintraub A; Rashid MU; Nord CE
Anaerobe; 2016 Dec; 42():119-122. PubMed ID: 27725229
[TBL] [Abstract][Full Text] [Related]
9. Assessment of pathogen frequency and resistance patterns among pediatric patient isolates: report from the 2004 SENTRY Antimicrobial Surveillance Program on 3 continents.
Fedler KA; Biedenbach DJ; Jones RN
Diagn Microbiol Infect Dis; 2006 Dec; 56(4):427-36. PubMed ID: 16938419
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR
J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
[TBL] [Abstract][Full Text] [Related]
11. In Vitro Activity of Solithromycin against Bordetella pertussis, an Emerging Respiratory Pathogen.
Hardy DJ; Vicino D; Fernandes P
Antimicrob Agents Chemother; 2016 Dec; 60(12):7043-7045. PubMed ID: 27620481
[TBL] [Abstract][Full Text] [Related]
12. Contemporary antimicrobial activity of triple antibiotic ointment: a multiphased study of recent clinical isolates in the United States and Australia.
Jones RN; Li Q; Kohut B; Biedenbach DJ; Bell J; Turnidge JD
Diagn Microbiol Infect Dis; 2006 Jan; 54(1):63-71. PubMed ID: 16368476
[TBL] [Abstract][Full Text] [Related]
13. The role of bacterial pathogens in pre-operative sepsis of acute mural appendicitis.
Omer EF; Arabi EY; Abdein ZS; Mekki ME
East Afr Med J; 1985 Jun; 62(6):379-85. PubMed ID: 4042948
[No Abstract] [Full Text] [Related]
14. Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008).
Rhomberg PR; Jones RN
Diagn Microbiol Infect Dis; 2009 Dec; 65(4):414-26. PubMed ID: 19833471
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of the new fluoroketolide solithromycin (CEM-101) against a large collection of clinical Neisseria gonorrhoeae isolates and international reference strains, including those with high-level antimicrobial resistance: potential treatment option for gonorrhea?
Golparian D; Fernandes P; Ohnishi M; Jensen JS; Unemo M
Antimicrob Agents Chemother; 2012 May; 56(5):2739-42. PubMed ID: 22354296
[TBL] [Abstract][Full Text] [Related]
16. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999).
Gales AC; Jones RN; Forward KR; Liñares J; Sader HS; Verhoef J
Clin Infect Dis; 2001 May; 32 Suppl 2():S104-13. PubMed ID: 11320451
[TBL] [Abstract][Full Text] [Related]
17. Determination of Disk Diffusion and MIC Quality Control Guidelines for Solithromycin, a Novel Fluoroketolide Antibacterial, against Neisseria gonorrhoeae.
Riedel S; Ross JE; Farrell DJ; Flamm RK; Jones RN
J Clin Microbiol; 2015 Dec; 53(12):3888-90. PubMed ID: 26378286
[TBL] [Abstract][Full Text] [Related]
18. Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations.
Biedenbach DJ; Jones RN
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):202-12. PubMed ID: 19321284
[TBL] [Abstract][Full Text] [Related]
19. The solithromycin journey-It is all in the chemistry.
Fernandes P; Martens E; Bertrand D; Pereira D
Bioorg Med Chem; 2016 Dec; 24(24):6420-6428. PubMed ID: 27595539
[TBL] [Abstract][Full Text] [Related]
20. Solithromycin (CEM-101): A New Fluoroketolide Antibiotic and Its Role in the Treatment of Gonorrhea.
Mancuso AM; Gandhi MA; Slish J
J Pharm Pract; 2018 Apr; 31(2):195-201. PubMed ID: 28490220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
